Literature DB >> 17985088

Diagnosis and differential diagnosis of hypergastrinemia.

Rudolf Arnold1.   

Abstract

The most frequent conditions of hypergastrinemia in man are the Zollinger-Ellison syndrome with autonomous gastrin hypersecretion by the tumour cell and reactive hypergastrinemia in type A autoimmune chronic atrophic gastritis with achlorhydria causing unrestrained gastrin release from the gastrin-producing antral G-cells. Both entities differ with respect to the pH in the gastric fluid, which is < 2 in patients with Zollinger-Ellison syndrome and neutral in type A gastritis. Other conditions with moderate hypergastrinemia as treatment with proton pump inhibitors, gastric outlet obstruction, previous vagotomy, chronic renal failure or short bowel syndrome are of minor clinical importance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17985088     DOI: 10.1007/s00508-007-0878-0

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   2.275


  17 in total

1.  Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.

Authors:  R Eissele; G Brunner; B Simon; E Solcia; R Arnold
Journal:  Gastroenterology       Date:  1997-03       Impact factor: 22.682

2.  Serum gastrin levels during long-term omeprazole treatment.

Authors:  H Koop; M Klein; R Arnold
Journal:  Aliment Pharmacol Ther       Date:  1990-04       Impact factor: 8.171

3.  Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.

Authors:  K D Bardhan; P Cherian; A E Bishop; J M Polak; H Romanska; M J Perry; A Rowland; M Thompson; P Morris; A Schneider; R Fischer; W Ng; R Lühmann; B McCaldin
Journal:  Am J Gastroenterol       Date:  2001-06       Impact factor: 10.864

4.  Prognostic value of initial fasting serum gastrin levels in patients with Zollinger-Ellison syndrome.

Authors:  A C Berger; F Gibril; D J Venzon; J L Doppman; J A Norton; D L Bartlett; S K Libutti; R T Jensen; H R Alexander
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

Review 5.  Gastrointestinal cells producing endocrine, neurocrine and paracrine messengers.

Authors:  L I Larsson
Journal:  Clin Gastroenterol       Date:  1980-09

6.  Hypergastrinemia of antral origin in duodenal ulcer.

Authors:  C B Lamers; C M Ruland; H J Joosten; H C Verkooyen; J H van Tongeren; J F Rehfeld
Journal:  Am J Dig Dis       Date:  1978-11

7.  Helicobacter pylori-associated exaggerated gastrin release in duodenal ulcer patients. The effect of bombesin infusion and urea ingestion.

Authors:  D Y Graham; A Opekun; G M Lew; P D Klein; J H Walsh
Journal:  Gastroenterology       Date:  1991-06       Impact factor: 22.682

8.  Antral gastrin cell hyperfunction and Helicobacter pylori infection.

Authors:  B Annibale; G Rindi; G D'Ambra; M Marignani; E Solcia; C Bordi; G Delle Fave
Journal:  Aliment Pharmacol Ther       Date:  1996-08       Impact factor: 8.171

9.  Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.

Authors:  E C Klinkenberg-Knol; H P Festen; J B Jansen; C B Lamers; F Nelis; P Snel; A Lückers; C P Dekkers; N Havu; S G Meuwissen
Journal:  Ann Intern Med       Date:  1994-08-01       Impact factor: 25.391

10.  Gastrin and somatostatin in Helicobacter pylori infected antral mucosa.

Authors:  L Odum; H D Petersen; I B Andersen; B F Hansen; J F Rehfeld
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

View more
  16 in total

1.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

2.  Hypergastrinemia--diagnosis and treatment.

Authors:  Bruno Niederle
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 3.  Diagnosis of Zollinger-Ellison syndrome: increasingly difficult.

Authors:  Tetsuhide Ito; Guillaume Cadiot; Robert T Jensen
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

4.  Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.

Authors:  David C Metz; Guillaume Cadiot; Pierre Poitras; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Endocr Oncol       Date:  2017-10-11

Review 5.  [Gastric neuroendocrine tumors. Endoscopic and surgical treatment].

Authors:  M B Niederle; B Niederle
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

6.  Unexplained refractory iron-deficiency anaemia in a 41-year-old woman.

Authors:  N de Matthaeis; G L Rapaccini; L Riccardi; D Pugliese
Journal:  BMJ Case Rep       Date:  2010-08-19

7.  Juvenile polyposis of the stomach--a novel cause of hypergastrinemia.

Authors:  Karen D Papay; Vincent G Falck; Steen S Poulsen; Remo Panaccione; Jens F Rehfeld; Martin A Storr
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-31       Impact factor: 46.802

Review 8.  Gastric acid hypersecretory states: recent insights and advances.

Authors:  Nauramy Osefo; Tetsuhide Ito; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2009-12

Review 9.  Population-based mechanistic prediction of oral drug absorption.

Authors:  Masoud Jamei; David Turner; Jiansong Yang; Sibylle Neuhoff; Sebastian Polak; Amin Rostami-Hodjegan; Geoffrey Tucker
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

10.  Syndromic versus non-syndromic sporadic gastrin-producing neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior.

Authors:  M Johannes Rosentraeger; Nele Garbrecht; Martin Anlauf; Andreas Raffel; Wolfram T Knoefel; Bertram Wiedenmann; Günter Klöppel
Journal:  Virchows Arch       Date:  2015-12-09       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.